



LucidQuest Intelligence
Accelerate your success

EADV 2026



2026

EADV 2026 Preview – Table of Contents

• <u>General Overview and Conference Themes</u>	<u>3-4</u>
• <u>Noteworthy Scientific presentations at EADV'26</u>	<u>5-37</u>
• <u>Key Topics From Notable Presentations</u>	<u>6-8</u>
• <u>Notable Presentations Information at EADV'26</u>	<u>9-37</u>
• <u>Noteworthy AI / ML Presentations</u>	<u>38-45</u>
• <u>Key AI / ML Themes</u>	<u>39-41</u>
• <u>Key AI/ML Presentations Information</u>	<u>42-45</u>
• <u>Get in touch with LucidQuest</u>	<u>46</u>



EADV 2026 – General Overview

- ➔ • **Comprehensive Disease Coverage:** Research will span inflammatory, infectious, pigmentary, oncologic, pediatric, and aesthetic dermatology, reflecting full-spectrum clinical and translational practice
- ➔ • **Expansion of Real-World Evidence:** Large registries and observational datasets will increasingly inform long-term safety, treatment durability, and real-world effectiveness across therapies
- ➔ • **Patient-Centred Outcomes Integration:** Studies will prioritize quality of life, adherence, mental health, and functional burden as key endpoints alongside clinical efficacy
- ➔ • **Advanced Therapeutic Landscape:** Biologics, JAK inhibitors, TYK2 inhibitors, and regenerative approaches will dominate innovation
- ➔ • **Procedural and Combination Approaches:** Laser, PRP, microneedling, and combination techniques will expand dermatologic treatment strategies
- ➔ • **Digital and AI Adoption:** Machine learning, AI-driven skincare, and digital health tools will increasingly shape diagnosis, risk prediction, and patient engagement



EADV 2026 – Conference Themes

- **Precision Targeting in Inflammatory Diseases:** Research will emphasize cytokine pathways, biomarkers, and optimized treatment sequencing strategies
- **Psoriasis Pipeline Acceleration:** Novel biologics and oral agents will expand treatment across psoriasis disease subtypes
- **Atopic Dermatitis Treatment Evolution:** Biologics, JAK inhibitors, and microbiome approaches will improve disease control outcomes
- **Alopecia Therapeutic Expansion:** Targeted therapies and regenerative strategies will advance treatment for diverse alopecia types
- **Pigmentation and Scar Management Advances:** Combination therapies will enhance outcomes in vitiligo, melasma, and scar conditions
- **Infectious and Venereology Focus:** Research will address sexually transmitted infections, fungal diseases, and dermatologic complications



Noteworthy Scientific presentations at EADV 2026





Key Topics From Notable Presentations (1/3)

- **Acne, Hidradenitis Suppurativa, Rosacea & Follicular Disorders:** (Systemic Inflammation and Targeted HS Care)

- Hidradenitis suppurativa and acne discussions are expected to expand toward systemic inflammation, microbiome disruption, and comorbidity-driven treatment selection. Phase 3 povorcitinib network data, IL-1 β targeting, GLP-1 meta-analysis, anti-TNF monitoring, isotretinoin safety studies, and rosacea genetic-risk analyses may shape future sequencing, patient stratification, and broader recognition of follicular disorders as systemic, quality-of-life-impacting diseases

- **Atopic Dermatitis, Eczema, Urticaria & Immuno-Inflammatory Dermatoses:** (Biologic Expansion and Barrier-Focused Control)

- Atopic dermatitis and immune-inflammatory dermatoses are expected to focus on durable biologic control, topical innovation, barrier repair, and biomarker-guided treatment. GLOBOSTAD, ADhope1, TRuE-AD4, COAST, and SHORE may position dupilumab, lebrikizumab, ruxolitinib, and amlitelimab across long-term management, while microbiome, antimicrobial peptide, JAK inhibitor, and psychodermatology studies broaden care beyond lesion clearance





Key Topics From Notable Presentations (2/3)

- ✓ **Psoriasis, Psoriatic Arthritis & Papulosquamous Disease:** (Oral Immunology and Long-Term Biologic Differentiation)
 - Psoriasis discussions are expected to emphasize oral immunology expansion, biologic durability, and precision treatment sequencing. ICONIC-ADVANCE 1/2, LATITUDE-PsO-3001/3002, CLEAR-1, DREAM, UnIMMited, PRO-SPIRIT, and APEX may position icotrokinra, zasocitinib, risankizumab, guselkumab, ixekizumab, and picankibart across plaque psoriasis and psoriatic arthritis, while biomarker, metabolic, and real-world adherence analyses refine long-term competitive differentiation and treatment optimization
- ✓ **Pigmentary Disorders, Hair/Nail Disease, Aesthetics, Scars & Procedural Dermatology (Regenerative Aesthetics and Precision Hair Restoration)**
 - Procedural dermatology discussions are expected to emphasize regenerative medicine, combination laser strategies, and long-term alopecia control. ALLEGRO, UP-AA, ROSE-G, and MELATIDE may position ritlecitinib, baricitinib, exosomes, PRP, stromal vascular fraction, tranexamic acid, and microneedling across vitiligo, melasma, scars, and androgenetic alopecia, while AI-guided skincare and multimodal aesthetic protocols expand personalized dermatologic intervention strategies



Key Topics From Notable Presentations (3/3)



- **Skin Cancer, Infections, Venereology, Pediatric, Genetic, Vascular & Other Dermatology** (Key Theme: Diagnostic Precision and Specialty Care Expansion)
 - Specialty dermatology discussions are expected to emphasize earlier diagnosis, surveillance, and targeted management across skin cancer, infections, vascular anomalies, and pediatric disease. PD-1/PD-L1 blockade, LC-OCT-guided cryosurgery, bath-water PUVA, sirolimus, syphilis screening, anogenital wart therapy, and pediatric phototherapy may refine integrated care pathways across complex dermatologic populations



Notable Presentations And Late-breaking Sessions At EADV 2026

Notable Presentations Information At EADV 2026

Acne, HS, Rosacea & Follicular Disorders (1/4)



Date	Author	Title
07 May 2026	Yasmine Farai	Role of the Cutaneous Microbiota and Environmental Factors in Acne: A Case-Control Study of 60 Patients
07 May 2026	Jonas Brinker	Digital media as an early but risky information source in the patient journey of hidradenitis suppurativa: a qualitative interview study
07 May 2026	Mohamed Khater	Impact of The Ceramide-Containing Acne Skincare Regimen on Acne Severity, Quality of Life, and Tolerability in a Hot, Dry Climate: An Egyptian Real-World Study
07 May 2026	Zuzana Nevoralova	Efficacy and Tolerance of a Product Containing SE Microbioma Complex® in Patients with Mild Acne- a Prospective, Uncontrolled Study
07 May 2026	Ana Luiza Mapurunga Gonçalves	Epidemiological and clinical profile of patients with acne scars: baseline data from a prospective interventional study
07 May 2026	Ana Luiza Mapurunga Gonçalves	Interobserver Reliability of Acne Scar Assessment Scales in a Split-Face Study Using Standardised In-Person Evaluation
07 May 2026	Joo Hee Lee	Efficacy and Safety of Human Skin Microbiome-Derived Strains as Topical Treatment for Acne: An In Vitro and In Vivo Study
07 May 2026	Anna Tekielak	Efficacy and Safety of Interleukin-1β-Targeted Therapy in a Patient with Hidradenitis Suppurativa and Concomitant Crohn's Disease: A Case Report

Notable Presentations Information At EADV 2026

Acne, HS, Rosacea & Follicular Disorders (2/4)



Date	Author	Title
07 May 2026	Simona Kordeva	Loss of efficacy of Adalimumab in Hidradenitis Suppurativa: focus on alternatives
07 May 2026	Anunchuda Prasartsak	A study evaluating sexual function in Thai male patients with moderate to severe acne vulgaris after receiving low-dose isotretinoin compared to doxycycline.
07 May 2026	Nour Haddar	Impact of hidradenitis suppurativa on patients' quality of life: A moroccan study of 15 cases
07 May 2026	Marianna Dashko	STUDYING SOME INDICATORS OF CYTOKINE PROFILE IN WOMEN WITH ACNE AFTER COVID-19
07 May 2026	Stanislava Sevostianova	Systemic metabolomic alterations in moderate-to-severe acne vulgaris: a pilot case-control study
07 May 2026	Or Dagan	Cardiovascular disease risk in hidradenitis suppurativa across treatment pathways: a large population-based cohort study
07 May 2026	Ayhan Ozan Özdemir	Targeting the Pathway or the Cytokine? First Network Meta-Analysis Incorporating Phase 3 Povorcitinib Data: Comparative Efficacy of JAK1 vs. IL-17 Inhibitors in Moderate-to-Severe Hidradenitis Suppurativa
07 May 2026	Gamal ELDUWEB	Assessment of the Efficacy, Safety, and Tolerability of Low-Dose Pulsed Oral Isotretinoin in Managing Acne Vulgaris

Notable Presentations Information At EADV 2026

Acne, HS, Rosacea & Follicular Disorders (3/4)



Date	Author	Title
07 May 2026	Koorosh Karimi	<u>Safety and efficacy of GLP-1-based therapies in Hidradenitis Suppurativa: A Systematic Review and Meta-analysis</u>
07 May 2026	Raslina Shrestha	<u>Psychiatric Outcomes After GLP-1 Receptor Agonist Initiation vs Metformin in Hidradenitis Suppurativa: All of Us Database Study</u>
07 May 2026	Bhavesht Lalan	<u>Effectiveness and Tolerability of Low-Dose Micronized Isotretinoin in Severe Facial Acne: A Post Hoc, Gender-Stratified Analysis of a Real-World Retrospective Electronic Medical Record Study</u>
07 May 2026	Bhavesht Lalan	<u>Effectiveness and Tolerability of Low-Dose Micronized Isotretinoin in Severe Facial Acne: A Post Hoc, Age-Stratified Analysis of a Real-World Retrospective Electronic Medical Record Study</u>
07 May 2026	Duc Van Le	<u>Immunogenicity and Therapeutic Drug Monitoring of Anti-TNF Therapy in Hidradenitis Suppurativa: A Retrospective Cohort Study</u>
07 May 2026	Yu Xuan Jin	<u>Safety and Efficacy of Cold Atmospheric Plasma for the Treatment of Acne Vulgaris: A Systematic Review and Meta-Analysis</u>
07 May 2026	Alireza Jafarzadeh	<u>Systematic Review on the Efficacy, Safety, and Relapse Rates of Procedural Therapies in Acne Vulgaris</u>
07 May 2026	Yuwei Huang	<u>Clinical Characteristics and Treatment Outcomes Associated with Family History in Hidradenitis Suppurativa: A Systematic Review and Cohort Study</u>

Notable Presentations Information At EADV 2026

Acne, HS, Rosacea & Follicular Disorders (4/4)



Date	Author	Title
07 May 2026	Alireza Jafarzadeh	<u>Investigating the Impact of Isotretinoin Treatment on Metabolic Syndrome Markers and Body Mass Index Changes in Patients with Severe Acne Vulgaris: A Prospective Study</u>
07 May 2026	Alireza Jafarzadeh	<u>A comprehensive systematic review on the efficacy, safety, tolerability, and relapse rates of modern procedural therapies for inflammatory and non-inflammatory acne vulgaris</u>
07 May 2026	Houda Zouaki	<u>Efficacy and Tolerability of Combined Blue and Red LED Therapy in Mild to Moderate Acne: A Prospective Descriptive Study</u>
07 May 2026	Helena Polena	<u>Comprehensive Dermatological and Ophthalmological Evaluation of a High-Tolerance Sunscreen: Clinical Benefits in Rosacea Patients with Sensitive Skin Across light to dark Phototypes in a Brazilian Study</u>
07 May 2026	Samine Maria Ruff	<u>Genetic liability for psychiatric, psychosocial, and cognitive phenotypes is associated with increased occurrence of rosacea in the Danish Blood Donor Study</u>
07 May 2026	Loan Thi Kieu Pham	<u>Comparative Efficacy of 10% Azelaic Acid Versus 1% Metronidazole in the Treatment of Mild to Moderate Rosacea: A Randomized Controlled Study in Vietnamese Patients</u>
07 May 2026	Yuanting Wang	<u>Clinical and Psychosocial Correlates of Subjective Symptoms in Rosacea: A Cross-sectional Study of 482 Patients</u>
07 May 2026	Gullu Gencebay	<u>Ocular Biometric Changes in Patients Receiving Systemic Isotretinoin: A Prospective Controlled Study</u>

Notable Presentations Information At EADV 2026

AD, Eczema, Urticaria & Immuno-Inflammatory Dermatoses (1/6)



Date	Author	Title
07 May 2026	Erkin Berkay Yilmaz	Clinical Characteristics, Management Strategies, and Outcomes of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: A Single-Center Retrospective Study
07 May 2026	Alireza Jafarzadeh	Efficacy of Cyclosporin in the Management of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review
07 May 2026	Silvia Mariel Ferrucci	Dupilumab Shows Sustained Effectiveness and Safety in Patients With Atopic Dermatitis: Real-World Insights From the Overall Population 3 Years Into the GLOBOSTAD Multinational Prospective Observational Study
07 May 2026	Meslina Almaci	Real-world comparison of dupilumab and tralokinumab in moderate-to-severe atopic dermatitis: a 12-month prospective observational study
07 May 2026	May-Li MacKinnon MacKinnon	Lebrikizumab provides clinically meaningful response in face and hands in adults and adolescents with moderate-to-severe atopic dermatitis: ADhope1 study
07 May 2026	Jasmin Giebe	Antimicrobial Peptides as Biomarkers for Predicting Treatment Response in Moderate to Severe Atopic Dermatitis: A Prospective Cohort Study
07 May 2026	Raoul Vyumvuhore	Barrier-Restorative Efficacy of a Biomimetic Ceramide-Based Lipid Blend in In Vitro and Ex Vivo Models of Epidermal Lipid Disruption
07 May 2026	May-Li MacKinnon MacKinnon	Lebrikizumab provides clinically meaningful response in adults and adolescents with moderate-to-severe atopic dermatitis: ADhope1 study primary results

Notable Presentations Information At EADV 2026

AD, Eczema, Urticaria & Immuno-Inflammatory Dermatoses (2/6)



Date	Author	Title
07 May 2026	Helena Polena	Benefits of an anti-relapse gel-cream intended for very dry, irritated to atopic sensitive skin: Results from clinical study in babies, children and teenagers in India and Argentina
07 May 2026	Jessica McClatchy	A retrospective cohort study of dupilumab dose extension in atopic dermatitis
07 May 2026	Jung Min Lee	Lifestyle Factors and Metabolic Comorbidities of Severe Adult Atopic Dermatitis: A Nationwide Population-based Study
07 May 2026	Stamatis Gregoriou	The impact of chronic hand eczema on work productivity and quality of life: a cross-sectional study
07 May 2026	Ping Liu	Real-World Disease Burden and Treatment Patterns in Moderate-to-Severe Atopic Dermatitis Uncontrolled by Topical Therapy: Results from the China Atopic Dermatitis Registry Study
07 May 2026	Mostafa Deif	Observational Study on the Efficacy of Ceramide-Based Moisturizing Cream for Dry to Very Dry Atopic Skin: Insights from the Egyptian Cohort
07 May 2026	Dhanyadhorn Kusonjai	Efficacy of 0.20% Centella asiatica Extract (ECa 233) Cream Compared with 1% Hydrocortisone Cream for Eczema: A Double-Blind Randomized Non-Inferiority Trial
07 May 2026	Yingyu Ding	Comparative efficacy of combined azathioprine and narrowband UVB at 311 nm

Notable Presentations Information At EADV 2026

AD, Eczema, Urticaria & Immuno-Inflammatory Dermatoses (3/6)



Date	Author	Title
07 May 2026	Khaled AlMusallam	Composite Inflammatory Biomarkers as Predictors of Disease Severity and Multimorbidity in Older Patients With Atopic Dermatitis: A Retrospective Cohort Study
07 May 2026	Terézia Thomová	Modulating the Skin Microbiome in Atopic Dermatitis: A Six-Month Comparative Study of JAK Inhibitors, Dupilumab, Cyclosporine A, and Topical Corticosteroids
07 May 2026	Karen Miller	Long-Term Disease Control and Safety With Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis Following Failure of Prior Topical Therapies: Results From the TRuE-AD4 Phase 3b Study
07 May 2026	Johanna Kalmari	Natural microbial diversity in lotion prevents winter-related worsening of atopic dermatitis: a randomized, placebo-controlled, double-blind clinical trial
07 May 2026	Irina Pivneva	A Machine Learning Study of Environmental and Socioeconomic Factors Predicting the Risk of Atopic Dermatitis Risk Using Canadian Population-Based Data
07 May 2026	Shreya Kempegowda	A randomized assessor-blinded triple arm pilot study to compare the efficacy of mometasone furoate 0.1% ointment versus crisaborole 2% ointment versus tofacitinib 2% ointment twice daily in patients with mild to moderate atopic dermatitis.
07 May 2026	Farah Khan	Efficacy of Different types of Moisturizers in Atopic dermatitis across the severity spectrum
07 May 2026	Niyaz Mostafa	A study of the predictors of disease duration of discoid eczema

Notable Presentations Information At EADV 2026

AD, Eczema, Urticaria & Immuno-Inflammatory Dermatoses (4/6)



Date	Author	Title
07 May 2026	Alireza Jafarzadeh	Evaluation of the Effect of Botulinum Toxin Injection in Aggravating or Improving Seborrheic Dermatitis Symptoms: A Prospective, Single-Arm Clinical Trial
07 May 2026	Katarzyna Korecka	The Application of Dermoscopy and Ultraviolet-Induced Fluorescence Dermoscopy (UVFD) in Pemphigus Diseases: An issue probing study
07 May 2026	Anqi Liu	Periungual Injection of the Novel IL-17A Inhibitor Xeligekimab Combined with Tofacitinib for Acrodermatitis Continua of Hallopeau (ACH): A Prospective, Real-World, 12-Week Study
07 May 2026	Leonie Kahlert	Lichen Sclerosus- a registry study
07 May 2026	sihame alaoui	Dermoscopy in Lichen Amyloidosis: Insights from a Case Study
07 May 2026	Özlem SU KUCUK	Clinical Predictors of Omalizumab Dose Requirement and Corticosteroid Dependence in Bullous Pemphigoid: A Real-World Cohort Study
07 May 2026	Camille Ysabel Bautista	Demographic and Clinical Profile of Allergic Contact Dermatitis Patients Who Tested Positive with Metal Allergy from a Tertiary Hospital: A 12 Year Retrospective Study
07 May 2026	Michelle Sze Yiu Leung	Effectiveness of Psychodermatologic Educational Modules on Atopic Dermatitis Patient Outcomes: A Randomized Controlled Trial

Notable Presentations Information At EADV 2026

AD, Eczema, Urticaria & Immuno-Inflammatory Dermatoses (5/6)



Date	Author	Title
07 May 2026	Aakankshya Kharel	A Randomized Controlled Trial Assessing the Impact of Expert-Led Virtual Support Groups on the Quality of Life of Patients with Vulvar Lichen Sclerosus
07 May 2026	Carsten Flohr	Janus kinase inhibitors (JAKi) improve sleep in people with atopic dermatitis: a systematic review of randomised clinical trial evidence
07 May 2026	Souha Denna	Online Misuse of Topical Corticosteroids: Results from an Internet-Based Questionnaire of 200 Users
07 May 2026	Fares Alammari	Topical corticosteroid phobia among the general population: a cross-sectional study using the TOPICOP scale
07 May 2026	Shaden Alqurashi	Efficacy and Safety of Dupilumab in Patients with Chronic Spontaneous Urticaria: A Systematic Review
07 May 2026	SK Shahriar Ahmed	A Prospective, Single-Arm, Self-Controlled, Interventional Study on Efficacy and Safety of Histaglobulin as Add-On Therapy in Chronic Spontaneous Urticaria
07 May 2026	Rukiye Serenay Öğretici	Discontinuation Anxiety and Medication Beliefs in Chronic Spontaneous Urticaria Patients on Long-Term Omalizumab: A Cross-Sectional Study

Notable Presentations Information At EADV 2026

AD, Eczema, Urticaria & Immuno-Inflammatory Dermatoses (6/6)



Date	Author	Title
07 May 2026	Simone Liguori	Clinical, serological and flowcytometric predictors of pemphigus relapse after rituximab: A retrospective study
07 May 2026	Nina Magnolo	Efficacy and safety of monotherapy amlitelimab, a non-depleting anti-OX40 ligand antibody, in moderate-to-severe atopic dermatitis: 24-week results from the pivotal COAST 1 and COAST 2 phase 3 trials and efficacy and safety of amlitelimab, a non-depleting anti-OX40 ligand antibody, in combination with topical therapy in participants with moderate-to-severe atopic dermatitis: 24-week results from the SHORE phase 3 trial

Notable Presentations Information At EADV 2026

Psoriasis, Psoriatic Arthritis & Papulosquamous Disease (1/5)



Date	Author	Title
07 May 2026	Vasiliki Nikolaou	Systemic psoriasis treatments and oncologic outcomes in immune checkpoint inhibitor-induced psoriasis: a multicenter study from the EADV Task Force "Dermatology for Cancer Patients"
07 May 2026	Maja Pavic	Beliefs About Medicines and Adherence to Biologic Therapy in Patients with Moderate-to-Severe Psoriasis: A Cross-Sectional Study
07 May 2026	Ieva Renata Jonaitytė	Six Years of Biologic Therapy for Moderate to Severe Plaque Psoriasis: A Real-World, Single-Center Study
07 May 2026	wensheng lu	Safety of guselkumab treatment in patients with moderate-to-severe plaque psoriasis combined with latent tuberculosis or inactive hepatitis B virus infection: a retrospective multicenter observational study
07 May 2026	Agostina Loiacono	Efficacy and Safety of Oral IL-23 Receptor Blockade With Icotrokinra in Plaque Psoriasis: Meta-analysis of Randomized Controlled Trials
07 May 2026	Myrto Korogiannaki	Durable Inhibition of Structural Damage Progression and Improvements in Joint Disease Activity With Guselkumab in Active and Erosive Psoriatic Arthritis: Week 48 Results From APEX
07 May 2026	Hagen Russ	Descriptive effectiveness of b/tsDMARDs, including ixekizumab, at 12 months for patients with psoriatic arthritis in the German cohort of the PRO-SPIRIT observational study
07 May 2026	Ren Qu	Efficacy and Safety of Secukinumab in the Treatment of Elderly Patients with Psoriasis and Comorbid Chronic Metabolic Diseases or Cardiac Dysfunction



Notable Presentations Information At EADV 2026

Psoriasis, Psoriatic Arthritis & Papulosquamous Disease (2/5)



Date	Author	Title
07 May 2026	Andrew Craver	Biologic switching in psoriasis: a national cohort study under a standardized national formulary
07 May 2026	Ceyda Tetik Aydoğdu	Effects of Biologic Agents on Nailfold Dermoscopic Features in Patients with Psoriasis: A Three-Year Observational Study
07 May 2026	Alireza Jafarzadeh	Comparative Efficacy and Safety of Biologics and Small Molecule Inhibitors in the Treatment of Moderate-to-Severe Psoriasis: A Systematic Review
07 May 2026	Ekaterina Grekova	Evaluation of systemic and biologic therapies in adult erythrodermic pityriasis rubra pilaris: a 10-year single-centre study in Russia
07 May 2026	Myrto Korogiannaki	Durability of Response With Icotrokinra, a Targeted Oral Peptide, in Adults With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the Phase 3, Placebo- and Active Comparator-Controlled ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2 Trials
07 May 2026	Chul Jong Park	Distinct Mortality Risks in Generalized Pustular Psoriasis and Palmoplantar Pustulosis: A Nationwide, Population-based, Cohort Study
07 May 2026	Khalid Alshareef	Efficacy and Safety of IL-12, IL-17, IL-12/23, and IL-23 Inhibitors for Moderate-to-Severe Psoriasis: A Systematic Review and Bayesian Network Meta-Analysis
07 May 2026	Paolo Gisondi	Identifying Psoriasis Patients at Risk for Psoriatic Arthritis: Results of an Italian Multidisciplinary Delphi Consensus

Notable Presentations Information At EADV 2026

Psoriasis, Psoriatic Arthritis & Papulosquamous Disease (3/5)



Date	Author	Title
07 May 2026	Juan Manuel Morón Ocaña	Early response to calcipotriol and betamethasone dipropionate PAD-cream at week 4: a post-hoc analysis from pooled MC2-01-C2 and MC2-01-C7 phase III trials
07 May 2026	Ekaterina Grekova	Clinical Characteristics, Triggers, and Comorbidities of Psoriatic Erythroderma: A Comparative Registry Study in Russia and Belarus
07 May 2026	Yanli Liu	A Multicenter, Randomized, Open-label, Phase 3 Study to Evaluate the Efficacy and Safety of SSGJ-608 in patients with moderate-to-severe plaque psoriasis
07 May 2026	Irene Stefanaki	Long-term outcomes of ixekizumab for the management of psoriasis in overweight and obese patients: a real-world, retrospective study
07 May 2026	Gabriel de Barros F Santos	Immunobiological therapy in moderate to severe psoriasis: a retrospective cohort study investigating the effects of drug distribution problems on disease relapse risk.
07 May 2026	Veerarat Punthitra	Efficacy and safety of cream containing sericin and turmeric in psoriasis patients
07 May 2026	Jisung Kim	Comparative Analysis of Clinical Characteristics and Therapeutic Outcomes in Patients with Psoriasis versus Psoriatic Arthritis : A Single Center Retrospective Study
07 May 2026	Yanli Liu	Efficacy and Safety of SSGJ-608 in Moderate-to-Severe Plaque Psoriasis: a Pivotal Multicenter, Randomized, Double-blind, Placebo-Controlled, Phase 3 Clinical Trial

Notable Presentations Information At EADV 2026

Psoriasis, Psoriatic Arthritis & Papulosquamous Disease (4/5)



Date	Author	Title
07 May 2026	Fadoua Chemsy	The psychological and socioeconomic impact of palmoplantar psoriasis versus vulgar psoriasis: a prospective comparative study
07 May 2026	Fadoua Chemsy	The occupational disability of palmoplantar psoriasis versus vulgar psoriasis: a prospective comparative study
07 May 2026	Pedro Martínez Arredondo	Calcipotriol/betamethasone cream for scalp psoriasis treatment: insights from a prospective Study.
07 May 2026	Sinu Mathachan	Efficacy of Tofacitinib in Three Children With Prurigo Nodularis and Its Mechanistic Rationale
07 May 2026	Melinda Gooderham	Zasocitinib, a once-daily oral TYK2 inhibitor, demonstrates rapid and reproducible improvements in body surface area (BSA) involvement in adults with moderate-to-severe plaque psoriasis: results from two phase 3 trials (LATITUDE-PsO-3001 and 3002)
07 May 2026	Matthias Augustin	The DREAM Study: First Real-World Data on the Impact of Risankizumab on Quality-of-Life Domains That Contribute to Cumulative Life Course Impairment in Patients With Moderate-to-Severe Plaque Psoriasis
07 May 2026	Deepa Venkitaramani	Safety and Efficacy of Risankizumab in Genital and Scalp Psoriasis in the UnIIMMited Phase 4 Randomized Clinical Trial at Week 52
07 May 2026	Salma Moujahid	Predictive factors of Methotrexate therapeutic failure in severe psoriasis: An analytical study of 42 cases



Notable Presentations Information At EADV 2026

Psoriasis, Psoriatic Arthritis & Papulosquamous Disease (5/5)



Date	Author	Title
07 May 2026	Yuling Shi	Changes in Metabolic Indicators in Psoriatic Patients Treated with Picankibart in the Phase 3 CLEAR-1 Trial
07 May 2026	Ingeborg Bachmann	Beyond skin deep: Baseline systemic immune-inflammatory index as predictor of treatment response of HRO350 in mild-to-moderate psoriasis. Results from the HeROPA study
07 May 2026	Melinda Gooderham	Once-daily oral zasocitinib demonstrates rapid and reproducible skin clearance with a consistent safety profile in moderate-to-severe plaque psoriasis: Results from two randomized phase 3 trials (LATITUDE-PsO-3001 and 3002)

Notable Presentations Information At EADV 2026



Hair/Nail Disease, Aesthetics, Scars & Procedural Dermatology (1/8)

Date	Author	Title
7 May 2026	Alireza Jafarzadeh	A Systematic Review of the Efficacy, Safety, and Satisfaction of Regenerative Medicine Treatments, Including Platelet-Rich Plasma, Stromal Vascular Fraction, and Stem Cell-Conditioned Medium for Hypertrophic Scars and Keloids
7 May 2026	Daryia Kairesheva	Assessment of the Safety and Tolerability of Combined Therapy with Calcipotriol and Microneedling in Patients with Vitiligo: A Prospective Study
7 May 2026	Jana Riemer	When Digital Meets Clinical: The Influence of Online Content on Vitiligo Patient Expectations. A Qualitative Study with Vitiligo Patients and Dermatologists in Germany
7 May 2026	Alireza Jafarzadeh	A Systematic Review of Case Series and Clinical Trials Investigating Regenerative Medicine for the Treatment of Vitiligo
7 May 2026	Alireza Jafarzadeh	A systematic review of case series and clinical trials investigating systemic oral or injectable therapies for the treatment of vitiligo
7 May 2026	Maryam Alabdullah	Therapeutic Efficacy of Mesenchymal Stem Cell-Derived Extracellular Vesicles for Wound Healing and Skin Regeneration: A Systematic Review of Meta-Analyses
7 May 2026	Büşra Özgül	Sequential Treatment With Tofacitinib, Baricitinib, And Upadacitinib In Alopecia Areata: A Real-World Cohort Study
7 May 2026	Ibraheem Azer	Efficacy and safety of tofacitinib in treatment of moderate to severe alopecia areata



Notable Presentations Information At EADV 2026



Hair/Nail Disease, Aesthetics, Scars & Procedural Dermatology (2/8)

Date	Author	Title
7 May 2026	Andi Nurul Fasty Batari	Topical Melatonin as an Anti-Aging Strategy: A Double-Blind Randomized Controlled Trial on Wrinkle Reduction and Skin Hydration Enhancement
7 May 2026	Alireza Jafarzadeh	Evaluating the Effectiveness and Safety of Pulsed Dye Laser Alone, Pulsed Dye Laser Combined with Botulinum Toxin A, and Pulsed Dye Laser Combined with Triamcinolone Injection in the Treatment of Hypertrophic Scars and Keloids: A Randomized Controlled Clinical Trial
7 May 2026	Alireza Jafarzadeh	Evaluation of the Efficacy, Safety, and Satisfaction Rate of Topical Latanoprost in Patients with Hypopigmented Burn Scars Treated with Fractional CO2 Laser: A Double-Blind Randomized Controlled Clinical Trial
7 May 2026	Alireza Jafarzadeh	Impact of Pentoxifylline on the Efficacy, Safety, Tolerability, and Patient Satisfaction of Fractional CO2 Laser in Patients with Hypertrophic and Keloid Burn Scars: A Pilot Blinded Randomized Controlled Trial
7 May 2026	Alireza Jafarzadeh	Evaluation of the Efficacy, Safety, and Satisfaction Rates of Platelet-Rich Plasma, Non-Cross-Linked Hyaluronic Acid, and their Combination in Patients with Acne Scars Treated with Fractional CO2 Laser: A Randomized, Double-Blind, Split-Face Comparative Study
7 May 2026	Alireza Jafarzadeh	Efficacy of Fractional CO2 Laser in Combination with Stromal Vascular Fraction (SVF) in the Treatment of Burn Scars: A Randomized Controlled Clinical Trial
7 May 2026	Alireza Jafarzadeh	The Efficacy, Satisfaction, and Safety of Carbon Dioxide (CO2) Fractional Laser in Combination with Pulsed Dye Laser (PDL) versus Each One Alone in the Treatment of Hypertrophic Burn Scars: A Single-Blinded Randomized Controlled Trial
7 May 2026	Alireza Jafarzadeh	Evaluation of the Efficacy, Safety, and Satisfaction Rates of Platelet-Rich Plasma, Non-Cross-Linked Hyaluronic Acid, and the Combination of Platelet-Rich Plasma and Non-Cross-Linked Hyaluronic Acid in Patients with Burn Scars Treated with Fractional CO2 Laser: A Randomized Controlled Clinical Trial



Notable Presentations Information At EADV 2026



Hair/Nail Disease, Aesthetics, Scars & Procedural Dermatology (3/8)

Date	Author	Title
7 May 2026	Alireza Jafarzadeh	Comparative Efficacy of Ablative and Non-Ablative Lasers for Atrophic, Hypertrophic, and Keloid Scars: A Systematic Review
7 May 2026	Xiaozhun Hang	Reducing post-inflammatory hyperpigmentation after fractional CO₂ laser in darker skin types using a novel adjunctive depigmenting regimen: a randomized evaluator-blinded study
7 May 2026	Emeka Okolo	Efficacy and Safety of Hyaluronic Acid Fillers for Liquid Rhinoplasty in Ethnic Skin: A Structured Review
7 May 2026	Daniela Bucur	From Botox or Hyaluronic Acid to Combined Aesthetic Medicine: The Role of Lasers in Achieving Low-Volume, High-Impact Results
7 May 2026	Karim Karray	A pilot Study on the Efficacy of Salmon-Derived Exosomes Delivered via Microneedling for the Treatment of Facial Hyperpigmentation
7 May 2026	Dr Jagdish Gindodia	Platelet-Rich Plasma for Steroid-Damaged Groin Skin: A Multimodal Comparative Study with Clinical, Sonographic, and Histopathologic Evidence
7 May 2026	Alireza Jafarzadeh	Evaluating the Effectiveness, Safety, and Satisfaction Rates of Phenol 90%, Trichloroacetic Acid 100%, and Radiofrequency in Lateral Matricectomy for the Treatment of Ingrown Toenails: A Triple-Arm Clinical Trial
7 May 2026	Priya Yadav	A randomized controlled trial to assess the effect of adding hypnoanaesthesia to existing standard infiltration anaesthetic technique in reducing pain and anxiety in children undergoing minor dermatosurgical procedures, as compared to standard infiltration anaesthetic technique alone



Notable Presentations Information At EADV 2026



Hair/Nail Disease, Aesthetics, Scars & Procedural Dermatology (4/8)

Date	Author	Title
7 May 2026	Wissal Souhail	Trichoscopic Characteristics of Hereditary Scalp Dysplasias: A Descriptive and Analytical Study
7 May 2026	Brett King	Complete Scalp Hair Regrowth and Predictors of Response in Patients With Alopecia Areata Receiving Ritlecitinib 50 mg up to 3 Years in the ALLEGRO Clinical Trial Program
7 May 2026	Angelina Sontag	Efficacy of Baricitinib in Adolescent Patients with Severe Alopecia Areata and Comorbid Atopic Dermatitis or Broader Atopic Background at 52 Weeks
7 May 2026	Ismahene Souissi	Non-Scarring Alopecia in Children: A Clinical and Dermoscopic Study
7 May 2026	Sae Hee Kim	New Onset of Hair Loss Disorders During the Coronavirus Disease 2019 Pandemic :A Korean Nationwide Population-Based Study
7 May 2026	Maiwenn L'Elchat	Flavonoid-Enriched Houseleek Extract (FEHE) to combat reactive hair loss: revealed efficacy on oxidative stress guardian NRF-2 in ex vivo hair follicle
7 May 2026	Ahmad Hussein	Trichoscopy of Alopecia Areata in Children: A Comparative Study of 61 Children and 61 Adults
7 May 2026	Melinda Gooderham	Facial Hair Regrowth and Health-Related Quality of Life in Males With Severe Alopecia Areata: First Report of Facial Hair Regrowth Outcomes Using Interim Results From the Phase 3 UP-AA Trial



Notable Presentations Information At EADV 2026



Hair/Nail Disease, Aesthetics, Scars & Procedural Dermatology (5/8)

Date	Author	Title
7 May 2026	Eirini Serakioti	Long-term effectiveness and maintenance of response to Baricitinib in adult patients with severe Alopecia Areata: A retrospective observational study in Greece (ROSE-G)
7 May 2026	Alireza Jafarzadeh	Investigating the Relationship Between Androgenetic Alopecia and Hair Shape, Color, and Thickness: A Case-Control Study
7 May 2026	Ahmed M Soliman	Impact of Scalp Hair Regrowth on Health-Related Quality of Life in Patients With Severe Alopecia Areata: Interim Results From the Phase 3 UP-AA Trial
7 May 2026	Karim Karray	Comparative Efficacy of Platelet-Rich Plasma, Polynucleotide, Salmon-Derived Exosomes, and Combination Therapy in Androgenic Alopecia: A Randomized Clinical and Histological Trial
7 May 2026	Alireza Jafarzadeh	Efficacy and Safety of Laser Therapy and Phototherapy in Cicatricial and Non-Cicatricial Alopecia: A Systematic Review
7 May 2026	Elisha Shrestha	Comparative Efficacy of 5% Minoxidil, Redensyl–Capixyl–Procapil (RCP), and Combination Therapy in Adult Male Androgenetic Alopecia: A Prospective Observational Study
7 May 2026	Karim Karray	Comparative Efficacy of Salmon derived exosomes versus polydeoxyribonucleotide in androgenic alopecia
7 May 2026	Yoram Harth	Efficacy of an AI-Algorithm-Assigned Customized Longevity Skincare Regimen in Women with Signs of Skin Aging: Interim Results from a 12-Week Clinical Study



Notable Presentations Information At EADV 2026



Hair/Nail Disease, Aesthetics, Scars & Procedural Dermatology (6/8)

Date	Author	Title
7 May 2026	Lenah AlMarzouk	Topical minoxidil reported hair discoloration: a cross-sectional study
7 May 2026	Ahmed Sadek	Real-World Efficacy, Tolerance, and Quality of Life Impact of a Mercaptonicotinoyl Glycine Containing Serum in Patients with Hyperpigmentation Disorders: A Prospective Observational Study
7 May 2026	Viktoria Eleftheriadou	Incidence of Cardiovascular Outcomes in People With Vitiligo: Evidence From a Large English Population-Based Cohort Study
7 May 2026	Sara Alghamdi	Efficacy and safety of Kligman's formula in the treatment of melasma: a systematic review and meta analysis
7 May 2026	Sara Alghamdi	Comparison of The efficacy and safety of fractional erbium: YAG laser in combination with Tranexamic acid delivery by different methods versus Tranexamic acid alone: A systematic review and meta-analysis
7 May 2026	Elizaveta Djahaia	Enhancing the Efficacy of Phototherapy in Vitiligo Using Microneedling with Latanoprost
7 May 2026	Sheng-Ni Chen	Investigating Vitiligo Stability and Exacerbation Risk After Aesthetic Procedures in Patients with Vitiligo: A Retrospective Observational Study
7 May 2026	Lipsa Kumari	A prospective cohort study to determine the prognostic factors in non-segmental vitiligo from a tertiary care centre.



Notable Presentations Information At EADV 2026



Hair/Nail Disease, Aesthetics, Scars & Procedural Dermatology (7/8)

Date	Author	Title
7 May 2026	Monisha Madhumita	MELATIDE Trial: Efficacy of Microneedling Combined with Topical GLP-1 Receptor Agonists for Recalcitrant Melasma
7 May 2026	Samreedhi Nath	Comparative Efficacy and safety of topical 5% methimazole versus 2% hydroquinone in melasma: A randomized split-face clinical and dermoscopic study
7 May 2026	Bhavesh Lalan	Efficacy and Safety of a Glycolic Acid-based Depigmenting Serum in Facial Post-Inflammatory Hyperpigmentation (PIH): A Prospective, Interventional Study in Indian Women
7 May 2026	Houda Talbi	Topical metformin for melasma: a prospective clinical study
7 May 2026	Dinesh Kumar Devaraj	Response of Combination Oral Isotretinoin and Q-Switched Nd:YAG Laser Toning in Lichen Planus Pigmentosus: A Retrospective Study in Skin Phototypes III, IV, and V
7 May 2026	Farhat Khan	Use of Intradermal Undiluted Tranexamic Acid in the Treatment of Melasma: A 24-Week Prospective Observational Study
7 May 2026	Gouri Anand	Double blinded randomized controlled trial to study the re-pigmentation in non-segmental vitiligo lesions using 0.1% tacrolimus, 0.2% tacrolimus, placebo in combination with excimer lamp
7 May 2026	Dr Jagdish Gindodia	Does Roller Mixer-Based PRP Preparation Improve Platelet Survival and Clinical Outcomes in Dermatology? A Prospective Clinical Study



Notable Presentations Information At EADV 2026



Hair/Nail Disease, Aesthetics, Scars & Procedural Dermatology (8/8)

Date	Author	Title
7 May 2026	Alireza Jafarzadeh	Effect of Topical Timolol on Healing of Immature Breast Scars After Mammoplasty: A Randomized Controlled Trial With Blinded Assessors and Patients
7 May 2026	Alireza Jafarzadeh	A Systematic Review of Procedural Treatments for Burn Scars in Children: Evaluating Efficacy, Safety, Standard Protocols, Average Sessions, and Tolerability Based on Clinical Studies
7 May 2026	Wei Jing Loo	Addressing the field, not just the lesion: A translational study of skin quality and actinic keratoses improvement
7 May 2026	Nina Magnolo	Impact of eyebrow and eyelash regrowth on patient-reported outcomes in patients with severe alopecia areata: Interim results from the phase 3 UP-AA trial



Notable Presentations Information At EADV 2026

Skin Cancer, Infections, Venereology & Other Dermatology (1/5)



Date	Author	Title
7 May 2026	Irina Pivneva	Environmental and Socioeconomic Determinants of Systemic Lupus Erythematosus Risk: A Machine Learning Study Using Canadian Population Data
7 May 2026	Laila Alami	Preventing Anti-Tuberculosis Treatment Interruption Through Early Dermatologic Management: A Prospective Study
7 May 2026	Wydad Boudi	An Unexpected Cutaneous Eruption Associated with Cemivil Therapy in Accelerated Phase Chronic Myeloid Leukemia
7 May 2026	Safa Gueroum	Efficacy of sirolimus in Klippel Trenaunay syndrome
7 May 2026	Isabella Viana Coimbra	Efficacy and safety of PD-1/PD-L1 blockade in patients with Merkel cell carcinoma
7 May 2026	Stephanie Kazan	Line-field confocal optical coherence tomography (LC-OCT) monitoring of cryosurgery in non-melanoma skin cancer: a retrospective study
7 May 2026	Hao-Kai Chuang	A Twenty-Year Multicenter Cohort Study of Subcutaneous Panniculitis-Like T-Cell Lymphoma
7 May 2026	Ela Gazal	Clinicopathologic Features and Clinical Outcomes of Non-Melanoma Cutaneous Metastases: A Single-Center Study

Notable Presentations Information At EADV 2026

Skin Cancer, Infections, Venereology & Other Dermatology (2/5)



Date	Author	Title
7 May 2026	Itziar Muelas Rives	<u>Second Cutaneous Neoplasms in Patients with a Personal History of Melanoma: A Single-Center Retrospective Observational Study</u>
7 May 2026	Kseniya Aulova	<u>Efficacy of bath-water PUVA in patients with early-stage mycosis fungoides</u>
7 May 2026	Catherine Shin Huey Chen	<u>Clinicopathologic Predictors of Invasive Disease and Recurrence in Extramammary Paget Disease: A Retrospective Cohort Study in an Asian Population</u>
7 May 2026	Gauri Mahabal	<u>Spectrum of Dermatological Consultations in Hematopoietic Stem Cell Transplant Recipients- A retrospective study</u>
7 May 2026	Foteini Moniati	<u>Treating Palmar Hyperhidrosis: A Comprehensive Systematic Review of Efficacy, Safety, and Patient-Centred Outcomes</u>
7 May 2026	Nisim Asayag	<u>A Cross-sectional Study of the Dermoscopic Attributes of Darier Disease</u>
7 May 2026	Minsu Kim	<u>Dermatologic Comorbidities in Patients with Neurofibromatosis Type 1: A Nationwide Population-Based Cohort Study</u>
7 May 2026	Samet Öner	<u>Management of Painful Segmental Cutaneous Leiomyoma in HLRCC Syndrome: Efficacy of Topical Calcium-Channel Blockers Validated by Cold-Provocation Test</u>

Notable Presentations Information At EADV 2026

Skin Cancer, Infections, Venereology & Other Dermatology (3/5)



Date	Author	Title
7 May 2026	Hanmant Barkate	Assessing the impact of dermatophytosis on Quality of Life using DLQI: A Real-world cross-sectional study from India
7 May 2026	Michaela Gabrielle Guieb	A Study of Excimer Laser with Itraconazole versus Itraconazole Monotherapy in the Management of Onychomycosis: A Single-Center, Assessor-Blinded, Randomized Control Trial
7 May 2026	Salma Mestassi	Cutaneous larva migrans: a clinical and dermoscopic study of a case treated with albendazole
7 May 2026	Karolina Harendarz-Chodyła	Diagnostic Challenges in Cutaneous Tuberculosis: A Case Study
7 May 2026	Julia Jia Rui Shen	Nationwide Retrospective Study of Tinea Capitis in Denmark: All Laboratory-Confirmed Cases in 2023
7 May 2026	Yu Xuan Jin	Safety and Efficacy of Needling Techniques for Cutaneous Warts: A Systematic Review
7 May 2026	Alireza Jafarzadeh	Regenerative medicine in the treatment of specific dermatologic disorders: a systematic review of randomized controlled clinical trials
7 May 2026	Nour Haddar	Adherence to photoprotection in patients with Xeroderma Pigmentosum: A questionnaire-based study.

Notable Presentations Information At EADV 2026

Skin Cancer, Infections, Venereology & Other Dermatology (4/5)



Date	Author	Title
7 May 2026	Kyle Mueller	Deaf patient use of dermatologic care: a single-center descriptive cohort study
7 May 2026	Ouissal Hormi	Study of parental practices regarding the use of natural or alternative remedies in the management of childhood dermatoses
7 May 2026	Mariem El Ayech	Evaluation of chatbot-generated patient information sheets for the treatment of infantile hemangioma: A comparative study
7 May 2026	Shreya Kempegowda	Efficacy and safety of oral sirolimus in vascular malformation: A prospective pilot assessor-blinded interventional study.
7 May 2026	Magdalini Louka	PROGNOSIS OF CUTANEOUS MASTOCYTOSIS IN CHILDHOOD: A LONG-TERM FOLLOW-UP STUDY
7 May 2026	Aakankshya Kharel	A Quasi-Experimental Cohort Study Assessing the Impact of School-Based Interventions on Sun-Safe Practices Among Elementary Students
7 May 2026	Gamal ELDUWEB	Efficacy, Safety, and Tolerability of Intralesional Vitamin D Injections for Treating Warts in Children
7 May 2026	Ghita Mikou	Phototherapy in pediatric dermatology: a retrospective descriptive study from a North African center

Notable Presentations Information At EADV 2026

Skin Cancer, Infections, Venereology & Other Dermatology (5/5)



Date	Author	Title
7 May 2026	Natalia Welc	<u>Sociodemographic, epidemiological and clinical analysis of patients treated for syphilis in the years 2017-2024: preliminary results.</u>
7 May 2026	Dina Ragab	<u>Topical Nitrizinc Complex Solution versus Spray-on Cryotherapy in the Management of Anogenital warts: A Comparative Study.</u>
7 May 2026	Aikaterini Chatziperrou	<u>Impact of Routine Multidisciplinary Screening on Syphilis Diagnosis: A Single-Center Comparative Study</u>
7 May 2026	Joonsoo Park	<u>Real-time Experience of Alitretinoin Use in Skin Inflammatory Diseases and Mycosis Fungoides: A Multicenter Retrospective Study</u>
7 May 2026	Justyna Szczęch	<u>Evaluating the Clinical Efficacy of a Multifunctional Regenerating Cream in Pediatric Skin Conditions: A Multicenter Observational Study</u>
7 May 2026	Thanos Emmanuel	<u>Efficacy and Safety of Topical Methenamine for Primary Focal Hyperhidrosis: A Systematic Review</u>





Themes from key AI / ML presentations at EADV 2026 (1/3)

- **AI in dermatology is expected to shift from experimental support tools toward clinically integrated systems for diagnosis, triage, education, workflow optimization, and precision assessment, while bias, safety, and validation challenges remain critical barriers**
- Check out the key AI / ML themes at EADV 2026 below:
- **Patient Self-Diagnosis and Care-Seeking:**
 - AI tools are set to influence acne self-treatment, suspicious lesion delays, and dermatology behavior, raising concerns around trust, accuracy, and delayed specialist review
- **Faster Diagnosis in Inflammatory Disease:**
 - AI applications in hidradenitis suppurativa, chronic urticaria, allergic dermatoses, and atopic dermatitis are expected to support earlier recognition and patient education
- **Population Risk Prediction:**
 - Two Canadian machine-learning studies are expected to assess environmental and socioeconomic predictors in atopic dermatitis and systemic lupus erythematosus risk



Themes from key AI / ML presentations at EADV 2026 (2/3)

- **Skin Cancer Referral Optimization:**

- A CE Class III AI medical device is positioned to improve urgent suspected skin cancer referral conversion through prospective, multi-centre diagnostic hub evaluation

- **Melanoma and Histology Quantification:**

- Human-eye versus AI evaluation of CD8 lymphocytes in CDKN2A-mutated melanomas is expected to test precision in immune-cell assessment

- **Bias and Equity in Diagnosis:**

- Paired multimodal AI model evaluation in skin of color is expected to expose safety, bias, and diagnostic reliability gaps

- **Synthetic Data and Vitiligo Assessment:**

- A sim-to-real deep learning approach is positioned to improve objective vitiligo assessment using synthetic data for real-world precision



Themes from key AI / ML presentations at EADV 2026 (3/3)

- **Generative AI in Education:**

- AI-generated imagery, chatbots, and LLM-based STI counseling are expected to test patient-facing accuracy, clarity, and acceptability

- **AI in Dermatology Workflow:**

- AI scribes and daily-practice tools are likely to address documentation efficiency, clinician workload, patient acceptance, and implementation barriers

- **Model Performance Benchmarking:**

- Frontier AI models on the UK Specialty Certificate Examination are expected to benchmark dermatology reasoning against expert-level standards



Noteworthy AI / ML presentations at EADV 2026

Notable Presentations At EADV 2026

AI / ML (1/3)



Date	Author	Title
7 May 2026	Souha Denna	Influence of Artificial Intelligence on Self-Diagnosis and Self-Treatment of Acne in Young Adults
7 May 2026	Madeleine Bull	Artificial intelligence to shorten the diagnosis of hidradenitis suppurativa
7 May 2026	Salma Moujahid	Use of artificial intelligence by patients in dermato-allergology
7 May 2026	Irina Pivneva	A Machine Learning Study of Environmental and Socioeconomic Factors Predicting the Risk of Atopic Dermatitis Risk Using Canadian Population-Based Data
7 May 2026	Chloe Jacklin	Use of a CE Class III Artificial Intelligence as a Medical Device in community-based diagnostic hubs to increase the conversion rate of urgent suspected skin cancer referrals - a prospective, multi-centre clinical evaluation
7 May 2026	Irina Pivneva	Environmental and Socioeconomic Determinants of Systemic Lupus Erythematosus Risk: A Machine Learning Study Using Canadian Population Data
7 May 2026	Helena Rivetti	Artificial Intelligence in Dermatological Diagnosis and Treatment

Notable Presentations At EADV 2026

AI / ML (2/3)



Date	Author	Title
7 May 2026	Luana-Andreea Nurla	Human-eye versus Artificial Intelligence Evaluation of CD8 Lymphocytes in CDKN2A-Mutated Melanomas
7 May 2026	Souha Denna	Influence of Artificial Intelligence on Delayed Consultation for Suspicious Skin Lesions in Young Adults
7 May 2026	Katherine Farquhar	Can Artificial Intelligence Accurately Depict Dermatological Disease? A Morphological Assessment of AI-Generated Imagery
7 May 2026	Vanessa Tran	Patient Acceptability, Perceptions, and Concerns Regarding Artificial Intelligence Scribes in Outpatient Dermatology Clinics
7 May 2026	Phyo Zaw Aung	Brains or Bots in Dermatology? Efficiency and Performance of Frontier AI Models on the UK Specialty Certificate Examination in Dermatology
7 May 2026	Ouissal Hormi	Contribution of Artificial Intelligence to Patient Education in Chronic Urticaria
7 May 2026	Ouissal Hormi	Artificial intelligence and allergic dermatoses: Reliable tool or technological illusion?

Notable Presentations At EADV 2026

AI / ML (3/3)



Date	Author	Title
7 May 2026	Apurv Khandelwal	When Safety Meets Bias: A Paired Evaluation of Multimodal AI Models for Dermatologic Diagnosis in Skin of Color
7 May 2026	Maksym Breslavets	Synthetic Data, Real Precision: A Sim-to-Real Deep Learning Approach for Objective Vitiligo Assessment
7 May 2026	Nikhil Mehta	Performance of a large language model-based AI chatbot for counseling patients with sexually transmitted infections and genital diseases
7 May 2026	Mariano Suppa	Artificial intelligence in daily practice

Strategic Insights and Strategy Development is our focus



COMPETITIVE STRATEGY
AND INTELLIGENCE



DIGITAL HEALTH, ARTIFICIAL
INTELLIGENCE AND IoE



GENE & CELL THERAPY



VACCINES & INFECTIOUS
DISEASES



INVESTMENT INSIGHTS

e: INFO@LQVENTURES.COM

w: WWW.LQVENTURES.COM